Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» immuno-oncology
immuno-oncology
FDA Considers Label Changes for Keytruda, Opdivo and Yervoy
RAPS.org
Wed, 07/12/17 - 02:41 pm
FDA
labeling
Keytruda
Opdivo
Yervoy
immuno-oncology
Merck
Bristol-Myers Squibb
Bristol-Myers Squibb adds new fundraising options, celeb partners to 'Ready. Raise. Rise.' I-O push
Fierce Pharma
Wed, 07/12/17 - 10:46 am
Bristol-Myers Squibb
immuno-oncology
celebrity endorsements
Prescribed Reading: I/O is the only game in town
BioPharma Dive
Sat, 07/8/17 - 10:02 am
immuno-oncology
Celgene
BeiGene
Endo International
Opana ER
Novartis
Orkambi
Vertex Pharmaceuticals
Merck
Bristol-Myers Squibb
Roche
Opdivo
Keytruda
Orencia
Can Celgene, Bluebird Keep Their Lead As Rivals Champ At The Bit?
Investors Business Daily
Sun, 07/2/17 - 10:07 am
Celgene
Bluebird Bio
Kite Pharma
Juno Therapeutics
CAR-T
immuno-oncology
bb2121
Investors — and AstraZeneca CEO Pascal Soriot — are getting a tad nervous as MYSTIC data loom
Endpoints
Thu, 06/29/17 - 09:23 am
investors
AstraZeneca
Pascal Soriot
Imfinzi
tremelimumab
immuno-oncology
clinical trials
2 Pharma Buyout Targets That May Surprise You
Motley Fool
Tue, 06/27/17 - 09:46 am
Biogen
Bristol-Myers Squibb
M&A
MS
multiple sclerosis
immuno-oncology
Bristol-Myers Squibb: Still Too Many Uncertainties In The I/O Space
Seeking Alpha
Wed, 06/14/17 - 09:02 pm
Bristol-Myers Squibb
immuno-oncology
Opdivo
How Merck hopes to win in I/O combos: Q&A with Roy Baynes
BioPharma Dive
Wed, 06/14/17 - 11:39 am
Merck
immuno-oncology
Keytruda
Opdivo
Bristol-Myers Squibb
Little Dragonfly bursts onto the I/O scene with a $33M Celgene deal and some of the biggest names in biotech
Endpoints
Mon, 06/12/17 - 09:44 am
Dragonfly Therapeutics
immuno-oncology
Celgene
The immuno-oncology market prepares for the inevitable question: 'What's next?'
Medical Marketing and Media
Thu, 06/1/17 - 02:51 pm
immuno-oncology
Keytruda
Merck
Opdivo
Bristol-Myers Squibb
Novartis sees gaps in cancer pipeline but is adamant it doesn’t need an I-O deal
Fierce Biotech
Thu, 06/1/17 - 09:01 am
Novartis
cancer
immuno-oncology
Does Incyte Have The Best Cancer Portfolio Among Mid-Cap Biotechs?
Barron's
Tue, 04/11/17 - 10:07 am
Incyte
epacadostat
olumiant
Jakafi
immuno-oncology
Celgene embraces MTAP cancer deal with fast-moving collaborator Agios
Endpoints
Mon, 03/13/17 - 10:16 am
Celgene
MTAP
Agios
immuno-oncology
Despite hype, still much to uncover about immunotherapy
BioPharma Dive
Sat, 03/11/17 - 11:49 am
immunotherapy
immuno-oncology
Novartis
M&A heating up among smaller I/O drugmakers
BioPharma Dive
Thu, 03/9/17 - 09:52 am
M&A
immuno-oncology
Heat Biologics
Pelican Therapeutics
Should Merck, BMS Fear Roche's Drug Becoming The I-O King?
Seeking Alpha
Fri, 02/24/17 - 09:10 am
Merck
Bristol-Myers Squibb
Roche
immuno-oncology
Tecentriq
AZ chief: Durvalumab's ready for a 'marketing battle' against I-O heavyweights Opdivo, Keytruda
Fierce Pharma
Tue, 02/7/17 - 10:25 am
immuno-oncology
AstraZeneca
durvalumab
Pascal Soriot
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
Incyte grabs control of a cancer drug from Calithera’s pipeline for $53M up front
Endpoints
Mon, 01/30/17 - 10:19 am
Inctye
Calithera
CB-1158
immuno-oncology
AstraZeneca angles for more competitive position in immuno-oncology
BioPharma Dive
Thu, 01/19/17 - 11:19 am
AstraZeneca
immuno-oncology
tremelimumab
durvalumab
Lilly and Merck Expand Immuno-Oncology Collaboration
Yahoo
Wed, 01/11/17 - 10:05 am
Eli Lilly
Merck
immuno-oncology
Lartruvo
Keytruda
Pages
« first
‹ previous
…
5
6
7
8
9
10
11
12
13
next ›
last »